Who We Are

The Experimental Cancer Treatment Unit (ECRU) was set up with the purpose of academically enhancing support for early phase clinical trials. Its focus is on providing a single point of engagement for the conduct of Phase 0/1/2 trials. The unit is part of the Department of Medical Oncology and was initiated in 2009.  The core team collaborates closely with  other clinicians and scientists committed to preclinical and clinical development of new anticancer drugs. Our core interests covers all solid tumours and lymphomas.

At ECRU, we coordinate the aspects of modern drug development from target discovery and validation, xenograft drug screening, clinical pharmacology and biomarker correlative clinical trials. This includes the ability to do sequential tumor biopsies for biomarker development in certain trials.

Mission of ECRU:

  • To bring new and novel agents to the patient’s bedside and develop new therapeutic options for cancer patients through scientifically driven sponsored and investigator-initiated research.
  • To facilitate the efficient execution of biomarker correlative early phase clinical trials in cancer patients
  • To provide a training platform for translation research both nationally and regionally